Bölüm
4

İMMÜN SİSTEM VE KONTROL NOKTALARI

Leyla TEKİN[1]

İMMUN SİSTEM

Bağışıklık sistemi, "kendinden olmayan" proteinleri veya antijenleri tanıyan ve bunlara karşı vücudu savunan çok yönlü biyokimyasal süreçler, çeşitli türlerde çözünebilir biyoaktif moleküller, sitokinler, proteinler ve hücrelerden oluşan kollektif bir yapıdır(1). Antijen organizmaya girdiklerinde immün yanıt oluşturan ve sonucunda ortaya çıkan antikor ve hücre yüzey molekülleri ile birleşme özelliği gösteren, organizmanın yapısına yabancı olan maddelerdir. Antijenin özgüllüğünü belirleyen ve kendisine özgül olan antikorları ile birleşmesini sağlayan kimyasal grup/gruplara, epitop/epitoplar adı verilir. Bir antijen molekülünün birden fazla epitopu bulunur

İmmün sistemin organ ve dokuları;

Başlıca iki grupta toplanır.

1- Santral lenfoid organlar: kemik iliği ve timus,lenfositlerin tüm özelliklerini kazanarak olgunlaştığı organlardır.

2- Periferik lenfoid organlar: dalak, lenf bezi, mukozal lenfoid doku (mucosa associated lymphoid tissue, MALT), edinsel immün yanıtın başladığı organlardır. İmmün hücreler santral organlarda olgunlaşır, periferik organlarda görevlerini yaparlar. İmmün sistemin tüm hücreleri tek bir kök hücreden gelişir. Kemik iliğinde pluripotent hemotopoetik kök hücreden daha özelleşmiş iki farklı öncül hücre oluşmaktadır. Bunlar myeloid progenitör hücre ve lenfoid progenitör hücredir. Myeloid progenitor hücreden eritrosit, trombosit, granülosit, monositler ve mast hücreleri gelişmektedir. Lenfoid progenitor hücreden lenfositler (T ve B) gelişmektedir. (Tablo 1)

1 Dr.Öğr.Üy.Leyla Tekin Muğla Sıtkı Koçman Üniversitesi Tıp Fakültesi dr.ltekin@hotmail.com

KAYNAKÇA

1. Murphy K., Travers P., Walport M.(2008). Principles of innate and adaptive immunity. Garland Science Taylor and Francis Group; *Janeway's Immunobiology*. (7th. pp 1-38) New York, NY, USA
2. Murphy K., Travers P., Walport M.(2008). Pattern recognition in the innate immune system. Garland Science Taylor and Francis Group; *Janeway's Immunobiology*. (7th. pp 39-108) New York, NY, USA
3. Dinarello C. A. Historical review of cytokines. *European Journal of Immunology*. 2007;37(supplement 1):34–45.
4. Wills-Karp M. Complement activation pathways: a bridge between innate and adaptive immune responses in asthma. *Proceedings of the American Thoracic Society*. 2007;4(3):247–251.
5. Sun J. C., Lanier L. L. Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity? *European Journal of Immunology*. 2009;39(8):2059–2064.
6. Murphy K., Travers P., Walport M.(2008). Structural variation in immunoglobulin constant regions. Garland Science Taylor and Francis Group; *Janeway's Immunobiology*. (7th. pp 143-213) New York, NY, USA
7. Chien Y.-H., Jores R., Crowley M. P. Recognition by γ/δ T cells. *Annual Review of Immunology*. 1996;14:511–532.
8. Koretzky G. A. Multiple roles of CD4 and CD8 in T cell activation. *Journal of Immunology*. 2010;185(5):2643–2644.
9. Luckheeram R.V., Zhou R., Verma A.D., et al. CD4 +T cells: differentiation and functions. *Clinical and Developmental Immunology*. 2012;2012:12.
10. Podojil J. R., Miller S. D. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. *Immunological Reviews*. 2009;229(1):337–355.
11. Janeway C. A., Jr., Travers P., Walport M., et al. (2001). . B-cell activation by armed helper T cells. Garland Science: *Immunobiology: The Immune System in Health and Disease*. 5th. New York, NY, USA.
12. Chen D. S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity*. 2013;39(1):1–10.
13. Dunn G. P., Koebel C. M., Schreiber R. D. Interferons, immunity and cancer immunoediting. *Nature Reviews Immunology*. 2006;6(11):836–848.
14. Pinho S. S., Reis C. A. Glycosylation in cancer: mechanisms and clinical implications. *Nature Reviews Cancer*. 2015;15(9):540–555.
15. Pio R., Corrales L., Lambris J. D. The role of complement in tumor growth. *Advances in Experimental Medicine and Biology*. 2014;772:229–262.
16. Kwan W.-H., Van Der Touw W., Heeger P. S. Complement regulation of T cell immunity. *Immunologic Research*. 2012;54(1–3):247–253.
17. Waldhauer I., Steinle A. NK cells and cancer immuno surveillance. *Oncogene*. 2008;27(45):5932–5943.
18. Gregory A. D., Houghton A. M. Tumor-associated neutrophils: new targets for cancer therapy. *Cancer Research*. 2011;71(7):2411–2416.
19. Terabe M., Berzofsky J.A. The role of NKT cells in tumor immunity. *Advances in Cancer Research*. 2008;101:277–348.
20. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. *Nature Reviews Cancer*. 2012;12(4):265–277.
21. Gogoi D., Chiplunkar S. V. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside. *The Indian Journal of Medical Research*. 2013;138:755–761.
22. Chaplin D. D. Overview of the immune response. *Journal of Allergy and Clinical Immunology*. 2010;125(2):S3–S23.
23. Sharpe AH.Mechanisms of costimulation. *Immunological Reviews* 2009;229(1):5–11.

24. Warrington R., Watson W., Kim H., et al. An introduction to immunology and immunopathology. *Allergy, Asthma & Clinical Immunology*. 2011;7, article S1
25. Harris T. J., Drake C. G. Primer on tumor immunology and cancer immunotherapy. *Journal for Immunotherapy of Cancer*. 2013;1, article 12
26. Minami Y., Kono T., Miyazaki T., et al. The IL-2 receptor complex: its structure, function, and target genes. *Annual Review of Immunology*. 1993;11:245–267.
27. Schroeder H.W., Jr., Cavacini L. Structure and function of immunoglobulins. *Journal of Allergy and Clinical Immunology*. 2010;125(2):41–52.
28. Crespo J., Sun H., Welling T.et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. *Current Opinion in Immunology*. 2013;25(2):214–221.
29. Contardi E., Palmisano G.L., Tazzari P.L., et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. *International Journal of Cancer*. 2005;117(4):538–550.
30. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science*. 2011;331(6024):1565–1570.
31. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. *Annual Review of Immunology*. 2004;22:329–360.
32. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. *Nature*. 2011;480(7378):480–489.
33. Mandal R., Chan T. A. Personalized oncology meets immunology: the path toward precision immunotherapy. *Cancer Discovery*. 2016;6(7):
34. Nelson B. H. IL-2, regulatory T cells, and tolerance. *The Journal of Immunology*. 2004;172(7):3983–3988.
35. Buchsel P.C., Forgey A., Grape F.B.,et al. Granulocyte macrophage colony-stimulating factor: current practice and novel approaches. *Clinical Journal of Oncology Nursing*. 2002;6(4):198–205.
36. Magee M. S., Snook A. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. *Discovery Medicine*. 2014;18(100):265–271.
37. Formenti S. C., Demaria S. Systemic effects of local radiotherapy. *The Lancet Oncology*. 2009;10(7):718–726.